{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-IP-Returns-and-Destruction”
},
“headline”: “SOP for IP Returns and Destruction in Clinical Trials”,
“description”: “This SOP defines standardized procedures for investigational product (IP) returns and destruction in clinical trials, ensuring accountability, compliance with ICH GCP, and adherence to FDA, EMA, CDSCO, and WHO guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for IP Returns and Destruction

Purpose

The purpose of this SOP is to establish procedures for the return and destruction of investigational products (IP) used in clinical trials. This ensures unused, expired, or damaged IP is managed responsibly, maintaining compliance with ethical, regulatory, and environmental standards.

Scope

This SOP applies to all clinical trial staff including investigators, pharmacists, coordinators, CROs, and sponsors involved in IP return, reconciliation, and destruction processes. It covers on-site destruction, sponsor return shipments, and third-party destruction with certification.

Responsibilities

• Principal Investigator (PI): Ensures IP returns and destruction follow approved procedures and are documented.
• Pharmacist/Authorized Designee: Manages IP reconciliation, prepares for return or destruction, and maintains logs.
• Study Coordinator: Files all destruction and return documentation in ISF and TMF.
• Sponsor/CRO: Authorizes destruction or arranges for IP return to sponsor-designated facilities.
• Quality Assurance Officer: Verifies IP destruction certificates and return logs during audits.

Accountability

The PI is accountable for ensuring investigational product returns and destruction are performed ethically, safely, and in compliance with ICH GCP, national regulations, and sponsor instructions.

Procedure

1. Preparation for IP Return/Destruction
Identify IP for return or destruction (unused, expired, or damaged).
Verify quantities against IP accountability records.
Segregate and label products for return or destruction.

2. IP Returns
Prepare Return Shipment Log (Annexure-1) including batch numbers, expiry dates, and quantities.
Package IP securely and ship to sponsor-designated location.
Maintain courier receipts and sponsor acknowledgment.

3. On-Site Destruction
Conduct destruction only after sponsor authorization.
Use methods compliant with local regulations (e.g., incineration).
Complete Certificate of Destruction (Annexure-2).

4. Third-Party Destruction
Engage licensed vendors authorized for pharmaceutical waste disposal.
Ensure witness of destruction by site or sponsor representative.
File destruction certificate in ISF and TMF.

5. Documentation
Record all activities in IP Return/Destruction Log (Annexure-3).
File approvals, shipment records, and certificates in ISF and TMF.

6. Archiving
Retain records for at least 5 years post-trial or as per national requirements.

Abbreviations

• SOP: Standard Operating Procedure
• PI: Principal Investigator
• IP: Investigational Product
• CRO: Clinical Research Organization
• ISF: Investigator Site File
• TMF: Trial Master File
• QA: Quality Assurance

Documents

1. Return Shipment Log (Annexure-1)
2. Certificate of Destruction (Annexure-2)
3. IP Return/Destruction Log (Annexure-3)

References

• ICH E6(R2) – Good Clinical Practice
• US FDA – Clinical Trial Guidance
• EMA Clinical Trial Regulation
• CDSCO Clinical Trial Rules, 2019
• WHO – Pharmaceutical Waste and Destruction Guidelines

Version: 1.0

Approval Section

Annexures

Annexure-1: Return Shipment Log

Annexure-2: Certificate of Destruction

Annexure-3: IP Return/Destruction Log

Revision History

For more SOPs visit: Pharma SOP